当前位置: X-MOL 学术Biomaterials › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Advances and perspectives in carrier-free nanodrugs for cancer chemo-monotherapy and combination therapy
Biomaterials ( IF 12.8 ) Pub Date : 2020-11-23 , DOI: 10.1016/j.biomaterials.2020.120557
Li Huang , Shaojing Zhao , Fang Fang , Ting Xu , Minhuan Lan , Jinfeng Zhang

Nanocarrier-based drug delivery systems hold impressive promise for biomedical application because of their excellent water dispersibility, prolonged blood circulation time, increased drug accumulation in tumors, and potential in combination therapeutics. However, most nanocarriers suffer from low drug-loading efficiency, poor therapeutic effectiveness, potential systematic toxicity, and unstable metabolism. As an alternative, carrier-free nanodrugs, completely formulated with one or more drugs, have attracted increasing attention in cancer therapy due to their advantage of improved pharmacodynamics/pharmacokinetics, reduced toxicity, and high drug-loading. In recent years, carrier-free nanodrugs have contributed to progress in a variety of therapeutic modalities. In this review, different common strategies for carrier-free nanodrugs preparation are first summarized, mainly including nanoprecipitation, template-assisted nanoprecipitation, thin-film hydration, spray-drying technique, supercritical fluid (SCF) technique, and wet media milling. Then we describe the recently reported carrier-free nanodrugs for cancer chemo-monotherapy or combination therapy. The advantages of anti-cancer drugs combined with other chemotherapeutic, photosensitizers, photothermal, immunotherapeutic or gene drugs have been demonstrated. Finally, a future perspective is introduced to highlight the existing challenges and possible solutions toward clinical application of currently developed carrier-free nanodrugs, which may be instructive to the design of effective carrier-free regimens in the future.



中文翻译:

用于癌症化学单一疗法和联合疗法的无载体纳米药物的研究进展和前景

基于纳米载体的药物输送系统具有出色的水分散性,延长的血液循环时间,增加的药物在肿瘤中的蓄积以及在联合治疗中的潜力,因此在生物医学应用中具有令人瞩目的前景。但是,大多数纳米载体的载药效率低,治疗效果差,潜在的系统毒性和代谢不稳定。作为替代方案,完全由一种或多种药物配制而成的无载体纳米药物由于具有改善的药效学/药代动力学,降低的毒性和高载药量的优势而在癌症治疗中引起了越来越多的关注。近年来,无载体的纳米药物促进了多种治疗方式的进步。在这篇评论中 首先总结了制备无载体纳米药物的不同常用策略,主要包括纳米沉淀,模板辅助纳米沉淀,薄膜水化,喷雾干燥技术,超临界流体(SCF)技术和湿介质研磨。然后,我们描述了最近报道的用于癌症化学单一疗法或联合疗法的无载体纳米药物。已经证明了抗癌药物与其他化学疗法,光敏剂,光热,免疫治疗或基因药物相结合的优势。最后,介绍了未来的观点,以突出当前开发的无载体纳米药物在临床应用方面的现有挑战和可能的解决方案,这可能对将来设计有效的无载体方案具有指导意义。主要包括纳米沉淀,模板辅助纳米沉淀,薄膜水化,喷雾干燥技术,超临界流体(SCF)技术和湿介质研磨。然后,我们描述了最近报道的用于癌症化学单一疗法或联合疗法的无载体纳米药物。已经证明了抗癌药物与其他化学疗法,光敏剂,光热,免疫治疗或基因药物相结合的优势。最后,介绍了未来的观点,以突出当前开发的无载体纳米药物在临床应用方面的现有挑战和可能的解决方案,这可能对将来设计有效的无载体方案具有指导意义。主要包括纳米沉淀,模板辅助纳米沉淀,薄膜水化,喷雾干燥技术,超临界流体(SCF)技术和湿介质研磨。然后,我们描述了最近报道的用于癌症化学单一疗法或联合疗法的无载体纳米药物。已经证明了抗癌药物与其他化学疗法,光敏剂,光热,免疫治疗或基因药物相结合的优势。最后,介绍了未来的观点,以突出当前开发的无载体纳米药物在临床应用方面的现有挑战和可能的解决方案,这可能对将来设计有效的无载体方案具有指导意义。和湿介质研磨。然后,我们描述了最近报道的用于癌症化学单一疗法或联合疗法的无载体纳米药物。已经证明了抗癌药物与其他化学疗法,光敏剂,光热,免疫治疗或基因药物相结合的优势。最后,介绍了未来的观点,以突出当前开发的无载体纳米药物在临床应用方面的现有挑战和可能的解决方案,这可能对将来设计有效的无载体方案具有指导意义。和湿介质研磨。然后,我们描述了最近报道的用于癌症化学单一疗法或联合疗法的无载体纳米药物。已经证明了抗癌药物与其他化学疗法,光敏剂,光热,免疫治疗或基因药物相结合的优势。最后,介绍了未来的观点,以突出当前开发的无载体纳米药物在临床应用方面的现有挑战和可能的解决方案,这可能对将来设计有效的无载体方案具有指导意义。

更新日期:2020-12-01
down
wechat
bug